Loading
A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Eisai Co., Ltd., active and no longer recruiting.
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04078295 by Eisai Co., Ltd., with 125 participants enrolled, started 2019-09-05 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7389-LF and Nivolumab.
Shares Deciphera Pharmaceuticals (Ono), Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.